Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.
Open | $74.95 |
Close | $74.70 |
Volume / Avg. | 429.66K / 1.01M |
Day Range | $74.46 - $75.72 |
52 Wk Range | 45.50 - 84.89 |
Market Cap | $7.89B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 51 |
Short Interest | 2.63% |
Days to Cover | 5.74 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Intra-Cellular Therapies (NASDAQ:ITCI) through any online brokerage.
Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS) and Pfizer (NYSE:PFE).
Intra-Cellular Therapies has a consensus price target of $91.31.
The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $74.7 last updated September 18, 2024 at 4:38 PM EDT.
There are no upcoming dividends for Intra-Cellular Therapies.
Intra-Cellular Therapies’s Q3 earnings are confirmed for Thursday, October 31, 2024.
There is no upcoming split for Intra-Cellular Therapies.
Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.